Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program.

Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S; DIAGRAM Consortium, Meigs JB, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetes. 2011 Apr;60(4):1340-8. doi: 10.2337/db10-1119. Epub 2011 Mar 4.

2.

Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants.

Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetes. 2016 Feb;65(2):520-6. doi: 10.2337/db15-0950. Epub 2015 Nov 2.

3.

Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.

Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, Lorenzo C, Pi-Sunyer X, Venditti E, Ye W; Diabetes Prevention Program Research Group.

Diabetes Care. 2017 Dec;40(12):1668-1677. doi: 10.2337/dc17-1116. Epub 2017 Oct 11. Erratum in: Diabetes Care. 2018 Feb 23;:. Diabetes Care. 2019 Apr;42(4):701.

4.

Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.

Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW; Diabetes Prevention Program Research Group.

PLoS Genet. 2012;8(8):e1002895. Epub 2012 Aug 30.

5.

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group.

Lancet. 2012 Jun 16;379(9833):2243-51. doi: 10.1016/S0140-6736(12)60525-X. Epub 2012 Jun 9.

6.

The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.

Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, Kahn SE, Kitabchi AE, Hanson RL, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2009 Feb;94(2):449-55. doi: 10.1210/jc.2008-1583. Epub 2008 Nov 18.

7.

Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.

Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF; Diabetes Prevention Program Research Group.

Diabetes Care. 2009 Sep;32(9):1583-8. doi: 10.2337/dc09-0523. Epub 2009 Jul 8.

8.

Relationship of body size and shape to the development of diabetes in the diabetes prevention program.

Diabetes Prevention Program Research Group.

Obesity (Silver Spring). 2006 Nov;14(11):2107-17.

9.

Type 2 diabetes-related genetic risk scores associated with variations in fasting plasma glucose and development of impaired glucose homeostasis in the prospective DESIR study.

Vaxillaire M, Yengo L, Lobbens S, Rocheleau G, Eury E, Lantieri O, Marre M, Balkau B, Bonnefond A, Froguel P.

Diabetologia. 2014 Aug;57(8):1601-10. doi: 10.1007/s00125-014-3277-x. Epub 2014 Jun 4.

PMID:
24893864
10.

Assessing the clinical utility of a genetic risk score constructed using 49 susceptibility alleles for type 2 diabetes in a Japanese population.

Imamura M, Shigemizu D, Tsunoda T, Iwata M, Maegawa H, Watada H, Hirose H, Tanaka Y, Tobe K, Kaku K, Kashiwagi A, Kawamori R, Maeda S.

J Clin Endocrinol Metab. 2013 Oct;98(10):E1667-73. doi: 10.1210/jc.2013-1642. Epub 2013 Aug 16.

PMID:
23956346
11.

Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program.

Pan Q, Delahanty LM, Jablonski KA, Knowler WC, Kahn SE, Florez JC, Franks PW; Diabetes Prevention Program Research Group.

Obesity (Silver Spring). 2013 Sep;21(9):E520-6. doi: 10.1002/oby.20459. Epub 2013 Jun 25.

12.

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2007 Apr;92(4):1502-9. Epub 2007 Jan 9.

13.

The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program.

O'Brien MJ, Whitaker RC, Yu D, Ackermann RT.

Prev Med. 2015 Aug;77:125-30. doi: 10.1016/j.ypmed.2015.05.017. Epub 2015 May 27.

14.

Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial.

Peter I, McCaffery JM, Kelley-Hedgepeth A, Hakonarson H, Reis S, Wagenknecht LE, Kopin AS, Huggins GS; Genetics Subgroup of the Look AHEAD Study.

Obesity (Silver Spring). 2012 Aug;20(8):1675-82. doi: 10.1038/oby.2012.11. Epub 2012 Feb 6.

15.

Combined effects of 17 common genetic variants on type 2 diabetes risk in a Han Chinese population.

Qi Q, Li H, Wu Y, Liu C, Wu H, Yu Z, Qi L, Hu FB, Loos RJ, Lin X.

Diabetologia. 2010 Oct;53(10):2163-6. doi: 10.1007/s00125-010-1826-5. Epub 2010 Jun 17.

PMID:
20556352
16.

Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC; Diabetes Prevention Program Research Group.

PLoS One. 2012;7(9):e44424. doi: 10.1371/journal.pone.0044424. Epub 2012 Sep 11.

17.

Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus.

Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, Kim C, Knowler WC, Christophi CA, Ratner R; Diabetes Prevention Program Research Group.

Diabetes Care. 2014 Apr;37(4):909-11. doi: 10.2337/dc13-0700. Epub 2013 Nov 22.

18.

Statistical power considerations in genotype-based recall randomized controlled trials.

Atabaki-Pasdar N, Ohlsson M, Shungin D, Kurbasic A, Ingelsson E, Pearson ER, Ali A, Franks PW.

Sci Rep. 2016 Nov 25;6:37307. doi: 10.1038/srep37307.

19.

A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes.

Hornbak M, Allin KH, Jensen ML, Lau CJ, Witte D, Jørgensen ME, Sandbæk A, Lauritzen T, Andersson Å, Pedersen O, Hansen T.

PLoS One. 2014 Aug 26;9(8):e104837. doi: 10.1371/journal.pone.0104837. eCollection 2014.

20.

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.

Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC; Diabetes Prevention Program Research Group.

Diabetes. 2010 Oct;59(10):2672-81. doi: 10.2337/db10-0543. Epub 2010 Aug 3.

Supplemental Content

Support Center